Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 523 articles:
HTML format



Single Articles


    November 2022
  1. DARMANI G, Drummond NM, Ramezanpour H, Saha U, et al
    Long-Term Recording of Subthalamic Aperiodic Activities and Beta Bursts in Parkinson's Disease.
    Mov Disord. 2022 Nov 24. doi: 10.1002/mds.29276.
    PubMed     Abstract available


  2. TALEBI AH, Ypinga JHL, De Vries NM, Nonnekes J, et al
    Specialized Versus Generic Allied Health Therapy and the Risk of Parkinson's Disease Complications.
    Mov Disord. 2022 Nov 24. doi: 10.1002/mds.29274.
    PubMed     Abstract available


  3. TANG Y, Li L, Hu T, Jiao F, et al
    In Vivo (18) F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia.
    Mov Disord. 2022 Nov 11. doi: 10.1002/mds.29273.
    PubMed     Abstract available


  4. KRAINC T, Monje MHG, Kinsinger M, Bustos BI, et al
    Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
    Mov Disord. 2022 Nov 9. doi: 10.1002/mds.29260.
    PubMed     Abstract available


  5. LEDONNE A, Massaro Cenere M, Paldino E, D'Angelo V, et al
    Morpho-Functional Changes of Nigral Dopamine Neurons in an alpha-Synuclein Model of Parkinson's Disease.
    Mov Disord. 2022 Nov 9. doi: 10.1002/mds.29269.
    PubMed     Abstract available


  6. HOENIG MC, Dzialas V, Drzezga A, van Eimeren T, et al
    The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?
    Mov Disord. 2022 Nov 7. doi: 10.1002/mds.29266.
    PubMed    


  7. TROCHE MS, Curtis JA, Sevitz JS, Dakin AE, et al
    Rehabilitating Cough Dysfunction in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2022 Nov 7. doi: 10.1002/mds.29268.
    PubMed     Abstract available


  8. PIZARRO GALLEGUILLOS BM, Mohamed W, Perinan MT
    The Glycoprotein GPNMB: A Secret Ingredient for Understanding Parkinson's Disease Etiology?
    Mov Disord. 2022 Nov 2. doi: 10.1002/mds.29264.
    PubMed    


  9. BOHNEN NI, Kanel P, van Emde Boas M, Roytman S, et al
    Vestibular Sensory Conflict During Postural Control, Freezing of Gait, and Falls in Parkinson's Disease.
    Mov Disord. 2022;37:2257-2262.
    PubMed     Abstract available


  10. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: No Association between Rare TWNK Variants and Parkinson's Disease in European Cohorts.
    Mov Disord. 2022;37:2319-2320.
    PubMed    


  11. SOTIRAKIS C, Conway N, Su Z, Villarroel M, et al
    Longitudinal Monitoring of Progressive Supranuclear Palsy using Body-Worn Movement Sensors.
    Mov Disord. 2022;37:2263-2271.
    PubMed     Abstract available


  12. LEYS F, Eschlbock S, Campese N, Mahlknecht P, et al
    Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?
    Mov Disord. 2022;37:2310-2312.
    PubMed    


    October 2022
  13. BARTL M, Dakna M, Schade S, Otte B, et al
    Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.
    Mov Disord. 2022 Oct 20. doi: 10.1002/mds.29257.
    PubMed     Abstract available


  14. VIVACQUA G, Mason M, De Bartolo MI, Wegrzynowicz M, et al
    Salivary alpha-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson's Disease.
    Mov Disord. 2022 Oct 19. doi: 10.1002/mds.29246.
    PubMed    


  15. HULZINGA F, Seuthe J, D'Cruz N, Ginis P, et al
    Split-Belt Treadmill Training to Improve Gait Adaptation in Parkinson's Disease.
    Mov Disord. 2022 Oct 14. doi: 10.1002/mds.29238.
    PubMed     Abstract available


  16. CLERET DE LANGAVANT L, Roze E, Petit A, Tressieres B, et al
    Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism.
    Mov Disord. 2022 Oct 10. doi: 10.1002/mds.29222.
    PubMed     Abstract available


  17. ZIMPRICH A
    LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?
    Mov Disord. 2022 Oct 5. doi: 10.1002/mds.29243.
    PubMed    


  18. KIM R, Kim H, Kim YK, Yoon EJ, et al
    Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease.
    Mov Disord. 2022;37:2099-2109.
    PubMed     Abstract available


  19. SAWAMURA M, Onoe H, Tsukada H, Isa K, et al
    Lewy Body Disease Primate Model with alpha-Synuclein Propagation from the Olfactory Bulb.
    Mov Disord. 2022;37:2033-2044.
    PubMed     Abstract available


  20. SOTO M, Iranzo A, Lahoz S, Fernandez M, et al
    Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases.
    Mov Disord. 2022;37:2086-2098.
    PubMed     Abstract available


    September 2022
  21. DANG X, Zhang Z, Luo XJ
    Mendelian Randomization Study Using Dopaminergic Neuron-Specific eQTL Nominates Potential Causal Genes for Parkinson's Disease.
    Mov Disord. 2022 Sep 29. doi: 10.1002/mds.29239.
    PubMed     Abstract available


  22. PAULY C, Glaab E, Hansen M, Martin-Gallausiaux C, et al
    Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease.
    Mov Disord. 2022 Sep 23. doi: 10.1002/mds.29212.
    PubMed    


  23. WILHELM E, Quoilin C, Derosiere G, Paco S, et al
    Corticospinal Suppression Underlying Intact Movement Preparation Fades in Parkinson's Disease.
    Mov Disord. 2022 Sep 19. doi: 10.1002/mds.29214.
    PubMed     Abstract available


  24. CHOU KL, Dayalu P, Koeppe RA, Gilman S, et al
    Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
    Mov Disord. 2022 Sep 14. doi: 10.1002/mds.29220.
    PubMed     Abstract available


  25. MILLS KA, Pontone GM
    The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?
    Mov Disord. 2022 Sep 14. doi: 10.1002/mds.29224.
    PubMed    


  26. MENG Y, Pople CB, Huang Y, Jones RM, et al
    Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study.
    Mov Disord. 2022 Sep 11. doi: 10.1002/mds.29190.
    PubMed     Abstract available


  27. LANSBURY P
    The Sphingolipids Clearly Play a Role in Parkinson's Disease, but Nature Has Made it Complicated.
    Mov Disord. 2022 Sep 10. doi: 10.1002/mds.29204.
    PubMed    


  28. LUO J, Wu H, Li J, Xian W, et al
    Joint Modeling Study Identifies Blood-Based Transcripts Link to Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2022 Sep 10. doi: 10.1002/mds.29213.
    PubMed     Abstract available


  29. ZHANG X, Xu J, Liu Y, Chen S, et al
    Diet Quality is Associated with Prodromal Parkinson's Disease Features in Chinese Adults.
    Mov Disord. 2022 Sep 7. doi: 10.1002/mds.29208.
    PubMed     Abstract available


  30. SENKEVICH K, Gan-Or Z
    No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts.
    Mov Disord. 2022 Sep 4. doi: 10.1002/mds.29216.
    PubMed    


  31. SEIFAR F, Dinasarapu AR, Jinnah HA
    Uric Acid in Parkinson's Disease: What Is the Connection?
    Mov Disord. 2022 Sep 3. doi: 10.1002/mds.29209.
    PubMed     Abstract available


  32. HARIZ M, Bronstein JM, Cosgrove GR, de Bie RMA, et al
    European Academy of Neurology/Movement Disorder Society-European Section Guidelines on Pallidotomy for Parkinson's Disease: Let's Be Accurate.
    Mov Disord. 2022 Sep 1. doi: 10.1002/mds.29210.
    PubMed    


    August 2022
  33. FERREIRA JJ, Poewe W, Rascol O, Stocchi F, et al
    Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
    Mov Disord. 2022 Aug 31. doi: 10.1002/mds.29193.
    PubMed     Abstract available


  34. COURTOIS E, Nguyen TTH, Fournier A, Carcaillon-Bentata L, et al
    Identifying Protective Drugs for Parkinson's Disease in Health-Care Databases Using Machine Learning.
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29205.
    PubMed     Abstract available


  35. LI D, Mastaglia FL, Yau WY, Chen S, et al
    Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29201.
    PubMed    


  36. GOLFRE ANDREASI N, Cilia R, Romito LM, Bonvegna S, et al
    Magnetic Resonance-Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early-Stage Tremor-Dominant Parkinson's Disease: A Pilot Study.
    Mov Disord. 2022 Aug 29. doi: 10.1002/mds.29200.
    PubMed     Abstract available


  37. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2022 Aug 27. doi: 10.1002/mds.29197.
    PubMed     Abstract available


  38. GAO CQ, Wang SN, Wang MM, Li JJ, et al
    Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson's Disease: A Diagnostic Accuracy Study.
    Mov Disord. 2022 Aug 25. doi: 10.1002/mds.29180.
    PubMed     Abstract available


  39. RUS T, Schindlbeck KA, Tang CC, Vo A, et al
    Stereotyped Relationship Between Motor and Cognitive Metabolic Networks in Parkinson's Disease.
    Mov Disord. 2022 Aug 23. doi: 10.1002/mds.29188.
    PubMed     Abstract available


  40. SIMMERING JE, Welsh MJ, Schultz J, Narayanan NS, et al
    Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29184.
    PubMed     Abstract available


  41. STEFANO DP, Franciotti R, Chiacchiaretta P, Ferretti A, et al
    Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29187.
    PubMed     Abstract available


  42. YUAN X, Yang Y, Liu C, Tian Y, et al
    Fine Particulate Matter Triggers alpha-Synuclein Fibrillization and Parkinson-like Neurodegeneration.
    Mov Disord. 2022 Aug 22. doi: 10.1002/mds.29181.
    PubMed     Abstract available


  43. REYES CJ, Asano K, Todd PK, Klein C, et al
    Repeat-Associated Non-AUG Translation of AGAGGG Repeats that Cause X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2022 Aug 16. doi: 10.1002/mds.29183.
    PubMed     Abstract available


  44. SAFARPOUR D, Brumbach BH, Arena M, Quinn J, et al
    Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study.
    Mov Disord. 2022 Aug 15. doi: 10.1002/mds.29176.
    PubMed     Abstract available


  45. SMIT JW, Basile P, Prato MK, Detalle L, et al
    Phase 1/1b Studies of UCB0599, an Oral Inhibitor of alpha-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.
    Mov Disord. 2022 Aug 12. doi: 10.1002/mds.29170.
    PubMed     Abstract available


  46. BANWINKLER M, Dzialas V, Hoenig MC, van Eimeren T, et al
    Gray Matter Volume Loss in Proposed Brain-First and Body-First Parkinson's Disease Subtypes.
    Mov Disord. 2022 Aug 9. doi: 10.1002/mds.29172.
    PubMed     Abstract available


  47. MCKEE KE, Gilbert RM, Spigle WA, Tilley BC, et al
    Inclusion of Non-English-Speaking Participants in Studies of Parkinson's Disease: A Call to Action.
    Mov Disord. 2022 Aug 5. doi: 10.1002/mds.29179.
    PubMed    


  48. TANG X, Gonzalez-Latapi P, Marras C, Visanji NP, et al
    Epigenetic Clock Acceleration Is Linked to Age at Onset of Parkinson's Disease.
    Mov Disord. 2022 Aug 3. doi: 10.1002/mds.29157.
    PubMed     Abstract available


  49. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Reply to: "Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations"?
    Mov Disord. 2022;37:1782.
    PubMed    


  50. GLEASON AM, Tayebi N, Lopez GJ, Sidransky E, et al
    Reply to: "Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1-Associated Parkinson's Disease".
    Mov Disord. 2022;37:1781-1782.
    PubMed    


  51. LI C, Lin J, Gu X, Hou Y, et al
    Mutation Screening of TFG in alpha-Synucleinopathy and Amyotrophic Lateral Sclerosis.
    Mov Disord. 2022;37:1756-1761.
    PubMed     Abstract available


  52. PAZ RM, Stahl AM, Rela L, Murer MG, et al
    D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
    Mov Disord. 2022;37:1693-1706.
    PubMed     Abstract available


    July 2022
  53. DAIDA K, Shimonaka S, Shiba-Fukushima K, Ogata J, et al
    alpha-Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid-Binding Property.
    Mov Disord. 2022 Jul 27. doi: 10.1002/mds.29162.
    PubMed     Abstract available


  54. TE VRUCHTE D, Sturchio A, Priestman DA, Tsitsi P, et al
    Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.
    Mov Disord. 2022 Jul 25. doi: 10.1002/mds.29163.
    PubMed     Abstract available


  55. SCHUMACHER-SCHUH AF, Bieger A, Okunoye O, Mok KY, et al
    Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29126.
    PubMed     Abstract available


  56. RAJAN R, Garg K, Srivastava AK, Singh M, et al
    Device-Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta-Analysis.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29160.
    PubMed     Abstract available


  57. BILLINGSLEY KJ, Alvarez Jerez P, Grenn FP, Bandres-Ciga S, et al
    Profiling the NOTCH2NLC GGC Repeat Expansion in Parkinson's Disease in the European Population.
    Mov Disord. 2022 Jul 22. doi: 10.1002/mds.29155.
    PubMed    


  58. LIU FT, Li XY, Lu JY, Wu P, et al
    (18) F-Florzolotau Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy-Parkinsonian Subtype.
    Mov Disord. 2022 Jul 21. doi: 10.1002/mds.29159.
    PubMed     Abstract available


  59. MARANO M, Anzini G, Musumeci G, Magliozzi A, et al
    Transcutaneous Auricular Vagus Stimulation Improves Gait and Reaction Time in Parkinson's Disease.
    Mov Disord. 2022 Jul 21. doi: 10.1002/mds.29166.
    PubMed    


  60. ILIEVA NM, De Miranda BR
    Rest and Digest-The Basal Role of Autophagy in Neurons and Its Relevance to Parkinson's Disease.
    Mov Disord. 2022 Jul 20. doi: 10.1002/mds.29165.
    PubMed    


  61. LU J, Ge J, Chen K, Sun Y, et al
    Consistent Abnormalities in Metabolic Patterns of Lewy Body Dementias.
    Mov Disord. 2022 Jul 20. doi: 10.1002/mds.29138.
    PubMed     Abstract available


  62. PEREZ-OLIVEIRA S, Alvarez I, Rosas I, Menendez-Gonzalez M, et al
    Intermediate and Expanded HTT Alleles and the Risk for alpha-Synucleinopathies.
    Mov Disord. 2022 Jul 19. doi: 10.1002/mds.29153.
    PubMed     Abstract available


  63. LUO S, Zou H, Stebbins GT, Schwarzschild MA, et al
    Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.
    Mov Disord. 2022 Jul 16. doi: 10.1002/mds.29154.
    PubMed     Abstract available


  64. DELVA A, Van Laere K, Vandenberghe W
    Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
    Mov Disord. 2022 Jul 12. doi: 10.1002/mds.29148.
    PubMed     Abstract available


  65. DOMENIGHETTI C, Douillard V, Sugier PE, Sreelatha AAK, et al
    The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease Revisited.
    Mov Disord. 2022 Jul 10. doi: 10.1002/mds.29133.
    PubMed     Abstract available


  66. SUBERT M, Simek M, Novotny M, Tykalova T, et al
    Linguistic Abnormalities in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2022 Jul 7. doi: 10.1002/mds.29140.
    PubMed     Abstract available


  67. PERCETTI M, Franco G, Monfrini E, Caporali L, et al
    TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study.
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29139.
    PubMed     Abstract available


  68. KOPYTOVA AE, Usenko TS, Baydakova GV, Nikolaev MA, et al
    Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations?
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29132.
    PubMed    


  69. DEUSCHL G, Antonini A, Costa J, Smilowska K, et al
    European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies.
    Mov Disord. 2022 Jul 6. doi: 10.1002/mds.29066.
    PubMed     Abstract available


  70. VIJIARATNAM N, Lawton M, Real R, Heslegrave AJ, et al
    Diabetes and Neuroaxonal Damage in Parkinson's Disease.
    Mov Disord. 2022;37:1568-1569.
    PubMed    


  71. BUHMANN C, Potter-Nerger M, Schulz R, Gerloff C, et al
    Reply to: "Diabetes and Neuroaxonal Damage in Parkinson's Disease".
    Mov Disord. 2022;37:1569-1570.
    PubMed    


  72. COCHEN DE COCK V, Dotov D, Damm L, Janaqi S, et al
    Reply to: "Is Gait Dysfunction Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?"
    Mov Disord. 2022;37:1576-1577.
    PubMed    


  73. KLARENDIC M, Kojovic M
    Reply to: "Neither Friend Nor Foe: Beekeeping and Parkinson's Disease".
    Mov Disord. 2022;37:1575.
    PubMed    


  74. NETUKOVA S, Rusz J, Ruzicka E, Krupicka R, et al
    Is Gait Dysfunction a Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?
    Mov Disord. 2022;37:1575-1576.
    PubMed    


  75. WASNER K, Smajic S, Ghelfi J, Delcambre S, et al
    Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation.
    Mov Disord. 2022;37:1405-1415.
    PubMed     Abstract available


  76. YU HJ, Thijssen E, van Brummelen E, van der Plas JL, et al
    A Randomized First-in-Human Study With UB-312, a UBITh(R) alpha-Synuclein Peptide Vaccine.
    Mov Disord. 2022;37:1416-1424.
    PubMed     Abstract available


  77. TAYLOR NL, Wainstein G, Quek D, Lewis SJG, et al
    The Contribution of Noradrenergic Activity to Anxiety-Induced Freezing of Gait.
    Mov Disord. 2022;37:1432-1443.
    PubMed     Abstract available


    June 2022
  78. LABANDEIRA-GARCIA JL, Parga JA
    Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene.
    Mov Disord. 2022 Jun 29. doi: 10.1002/mds.29137.
    PubMed     Abstract available


  79. PINEDA-PARDO JA, Gasca-Salas C, Fernandez-Rodriguez B, Rodriguez-Rojas R, et al
    Striatal Blood-Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study.
    Mov Disord. 2022 Jun 28. doi: 10.1002/mds.29134.
    PubMed     Abstract available


  80. POHL EDR, Upadhyay N, Kobeleva X, Purrer V, et al
    Coherent Structural and Functional Network Changes after Thalamic Lesions in Essential Tremor.
    Mov Disord. 2022 Jun 23. doi: 10.1002/mds.29130.
    PubMed     Abstract available


  81. WANG P, Pan J, Luo Q, Chen J, et al
    A 10-Year Community-Based Study of Leucine-Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease.
    Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29127.
    PubMed     Abstract available


  82. STRAKA I, Svantnerova J, Minar M, Stankova S, et al
    Neurodevelopmental Gene-Related Dystonia-Parkinsonism with Onset in Adults: A Case with NAA15 Variant.
    Mov Disord. 2022 Jun 22. doi: 10.1002/mds.29125.
    PubMed    


  83. XIE A, Ensink E, Li P, Gordevicius J, et al
    Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms.
    Mov Disord. 2022 Jun 20. doi: 10.1002/mds.29128.
    PubMed     Abstract available


  84. LUO S, Goetz CG, Choi D, Aggarwal S, et al
    Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.
    Mov Disord. 2022 Jun 18. doi: 10.1002/mds.29129.
    PubMed     Abstract available


  85. COKU I, Mutez E, Eddarkaoui S, Carrier S, et al
    Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
    Mov Disord. 2022 Jun 16. doi: 10.1002/mds.29124.
    PubMed     Abstract available


  86. OLSON JW, Nakhmani A, Irwin ZT, Edwards LJ, et al
    Cortical and Subthalamic Nucleus Spectral Changes During Limb Movements in Parkinson's Disease Patients with and Without Dystonia.
    Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29057.
    PubMed     Abstract available


  87. ATHAUDA D, Evans J, Wernick A, Virdi G, et al
    The Impact of Type 2 Diabetes in Parkinson's Disease.
    Mov Disord. 2022 Jun 14. doi: 10.1002/mds.29122.
    PubMed     Abstract available


  88. AJALIN RM, Al-Abdulrasul H, Tuisku JM, Hirvonen JES, et al
    Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [(18) F]FMPEP-d2.
    Mov Disord. 2022 Jun 8. doi: 10.1002/mds.29117.
    PubMed     Abstract available


  89. RINNE JO, Jucaite A, Cselenyi Z, Farde L, et al
    Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy.
    Mov Disord. 2022 Jun 6. doi: 10.1002/mds.29078.
    PubMed    



  90. The PSG 32nd Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders.
    Mov Disord. 2022;37 Suppl 1:S1-S36.
    PubMed    


  91. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Reply to: "Risk Disclosure in Prodromal Parkinson's Disease".
    Mov Disord. 2022;37:1327.
    PubMed    


  92. MORRIS LA, O'Callaghan C, Le Heron C
    Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease.
    Mov Disord. 2022;37:1149-1163.
    PubMed     Abstract available


    May 2022
  93. HOBSON DE, Del Bigio MR
    Beekeeper Parkinsonism.
    Mov Disord. 2022 May 31. doi: 10.1002/mds.29076.
    PubMed    


  94. LI C, Hou Y, Ou R, Gu X, et al
    Genetic Determinants of Survival in Parkinson's Disease in the Asian Population.
    Mov Disord. 2022 May 26. doi: 10.1002/mds.29069.
    PubMed     Abstract available


  95. DU G, Wang E, Sica C, Chen H, et al
    Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
    Mov Disord. 2022 May 25. doi: 10.1002/mds.29062.
    PubMed     Abstract available


  96. YANG X, Ai P, He X, Mo C, et al
    Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
    Mov Disord. 2022 May 24. doi: 10.1002/mds.29063.
    PubMed     Abstract available


  97. KIM R, Kim HJ, Shin JH, Lee CY, et al
    Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease.
    Mov Disord. 2022 May 21. doi: 10.1002/mds.29056.
    PubMed     Abstract available


  98. SMEYNE RJ, Eells JB, Chatterjee D, Byrne M, et al
    COVID-19 infection enhances susceptibility to oxidative-stress induced parkinsonism.
    Mov Disord. 2022 May 17. doi: 10.1002/mds.29116.
    PubMed     Abstract available


  99. YE R, O'Callaghan C, Rua C, Hezemans FH, et al
    Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders.
    Mov Disord. 2022 May 16. doi: 10.1002/mds.29072.
    PubMed     Abstract available


  100. MAHLKNECHT P, Foltynie T, Limousin P, Poewe W, et al
    How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
    Mov Disord. 2022 May 12. doi: 10.1002/mds.29052.
    PubMed     Abstract available


  101. YAMASHITA R, Beck G, Yonenobu Y, Inoue K, et al
    TDP-43 Proteinopathy Presenting with Typical Symptoms of Parkinson's Disease.
    Mov Disord. 2022 May 9. doi: 10.1002/mds.29048.
    PubMed     Abstract available


  102. SOSSI V, Patterson JR, McCormick S, Kemp CJ, et al
    Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease.
    Mov Disord. 2022 May 7. doi: 10.1002/mds.29051.
    PubMed     Abstract available


  103. WANG S, Unnithan S, Bryant N, Chang A, et al
    Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29043.
    PubMed     Abstract available


  104. PAN Y, Xue J, Chen J, Zhang X, et al
    Assessment of GGC Repeat Expansion in GIPC1 in Patients with Parkinson's Disease.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29041.
    PubMed    


  105. FILIPPI M, Balestrino R, Basaia S, Agosta F, et al
    Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
    Mov Disord. 2022 May 6. doi: 10.1002/mds.29047.
    PubMed     Abstract available


  106. ZHOU X, Liu Z, Zhou X, Xiang Y, et al
    The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics.
    Mov Disord. 2022 May 3. doi: 10.1002/mds.29037.
    PubMed     Abstract available


  107. STEINHARDT J, Hanssen H, Heldmann M, Sprenger A, et al
    Prodromal X-Linked Dystonia-Parkinsonism is Characterized by a Subclinical Motor Phenotype.
    Mov Disord. 2022 May 2. doi: 10.1002/mds.29033.
    PubMed     Abstract available


  108. MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
    Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations".
    Mov Disord. 2022;37:1119-1120.
    PubMed    


  109. GRISANTI S, Ferri L, Cavallieri F, Fioravanti V, et al
    Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Mov Disord. 2022;37:1117-1118.
    PubMed    


  110. LAANSMA MA, Bright JK, Jahanshad N, Thompson PM, et al
    Reply to: "Parkinson's Disease, Premature Mortality, and Amygdala".
    Mov Disord. 2022;37:1111-1112.
    PubMed    


  111. RAO SC, Pattipati S, Salim A, Gutierrez N, et al
    Promoting Gender Inclusivity: A Questionnaire for Women's Health Factors in Parkinson's Disease.
    Mov Disord. 2022;37:1112-1113.
    PubMed    


  112. SCORZA FA, de Almeida AG, Scorza CA, Finsterer J, et al
    Parkinson's Disease, Premature Mortality, and Amygdala.
    Mov Disord. 2022;37:1110-1111.
    PubMed    


  113. DARWEESH SKL, Vermeulen R, Bloem BR, Peters S, et al
    Exposure to Pesticides Predicts Prodromal Feature of Parkinson's Disease: Public Health Implications.
    Mov Disord. 2022;37:883-885.
    PubMed    


  114. SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
    Reply to: "Promoting Gender Inclusivity: A questionnaire for Women's Health Factors in Parkinson's Disease".
    Mov Disord. 2022;37:1113.
    PubMed    


  115. FOFFANI G
    An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2022;37:1105-1106.
    PubMed    


  116. ALZGHOOL OM, van Dongen G, van de Giessen E, Schoonmade L, et al
    alpha-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
    Mov Disord. 2022;37:936-948.
    PubMed     Abstract available


  117. GANAPATHY S R, Levova K, Kotackova L, Trnka J, et al
    Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2022;37:983-992.
    PubMed     Abstract available


  118. TODISCO M, Cosentino G, Scardina S, Fresia M, et al
    Diagnostic and Prognostic Value of External Anal Sphincter EMG Patterns in Multiple System Atrophy.
    Mov Disord. 2022;37:1069-1074.
    PubMed     Abstract available


  119. GAURAV R, Pyatigorskaya N, Biondetti E, Valabregue R, et al
    Deep Learning-Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2022;37:1064-1069.
    PubMed     Abstract available


    April 2022
  120. BANDRES-CIGA S
    Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics.
    Mov Disord. 2022 Apr 30. doi: 10.1002/mds.29042.
    PubMed    


  121. TANIMURA A, Shen W, Wokosin D, Surmeier DJ, et al
    Pathway-Specific Remodeling of Thalamostriatal Synapses in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2022 Apr 29. doi: 10.1002/mds.29030.
    PubMed     Abstract available


  122. KARAGIANIS JL
    Re: Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2022 Apr 28. doi: 10.1002/mds.29038.
    PubMed    


  123. LANGE LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, et al
    Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.
    Mov Disord. 2022 Apr 28. doi: 10.1002/mds.28982.
    PubMed     Abstract available


  124. KOLMANCIC K, Zupancic NK, Trost M, Flisar D, et al
    Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
    Mov Disord. 2022 Apr 18. doi: 10.1002/mds.29028.
    PubMed     Abstract available


  125. YASSINE S, Gschwandtner U, Auffret M, Achard S, et al
    Functional Brain Dysconnectivity in Parkinson's Disease: A 5-Year Longitudinal Study.
    Mov Disord. 2022 Apr 14. doi: 10.1002/mds.29026.
    PubMed     Abstract available


  126. RAMIREZ J, Berberian SA, Breen DP, Gao F, et al
    Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients.
    Mov Disord. 2022 Apr 11. doi: 10.1002/mds.29010.
    PubMed     Abstract available


  127. QUATTRONE A, Bianco MG, Antonini A, Vaillancourt DE, et al
    Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
    Mov Disord. 2022 Apr 11. doi: 10.1002/mds.28992.
    PubMed     Abstract available


  128. UYAR M, Lezius S, Buhmann C, Potter-Nerger M, et al
    Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study).
    Mov Disord. 2022 Apr 6. doi: 10.1002/mds.29009.
    PubMed     Abstract available


  129. BARBA L, Paolini Paoletti F, Bellomo G, Gaetani L, et al
    Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.
    Mov Disord. 2022;37:669-683.
    PubMed     Abstract available


  130. THIJSSEN E, den Heijer J, Puibert D, Moss L, et al
    A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
    Mov Disord. 2022;37:790-798.
    PubMed     Abstract available


  131. GRIJALVA RM, Pham NTT, Huang Q, Martin PR, et al
    Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2022;37:702-712.
    PubMed     Abstract available


    March 2022
  132. CHOUGAR L, Arsovic E, Gaurav R, Biondetti E, et al
    Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Mov Disord. 2022 Mar 29. doi: 10.1002/mds.28988.
    PubMed     Abstract available


  133. LE HERON C, MacAskill MR, Myall DJ
    Reply to: "An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis".
    Mov Disord. 2022 Mar 28. doi: 10.1002/mds.28989.
    PubMed    


  134. XU Y, Feeney MP, Surface M, Novak D, et al
    Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study.
    Mov Disord. 2022 Mar 26. doi: 10.1002/mds.28990.
    PubMed     Abstract available


  135. SIGURDSSON HP, Yarnall AJ, Galna B, Lord S, et al
    Gait-Related Metabolic Covariance Networks at Rest in Parkinson's Disease.
    Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28977.
    PubMed     Abstract available


  136. NAKANO Y, Hirano S, Kojima K, Li H, et al
    Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders.
    Mov Disord. 2022 Mar 14. doi: 10.1002/mds.28981.
    PubMed     Abstract available


  137. LUAN M, Sun Y, Chen J, Jiang Y, et al
    Diagnostic Value of Salivary Real-Time Quaking-Induced Conversion in Parkinson's Disease and Multiple System Atrophy.
    Mov Disord. 2022 Mar 12. doi: 10.1002/mds.28976.
    PubMed     Abstract available


  138. MURTOMAKI K, Mertsalmi T, Jaakkola E, Makinen E, et al
    Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease.
    Mov Disord. 2022 Mar 11. doi: 10.1002/mds.28986.
    PubMed     Abstract available


  139. STRANIERO L, Rimoldi V, Monfrini E, Bonvegna S, et al
    Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.
    Mov Disord. 2022 Mar 9. doi: 10.1002/mds.28987.
    PubMed     Abstract available


  140. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Erratum to "Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Approach".
    Mov Disord. 2022 Mar 4. doi: 10.1002/mds.28974.
    PubMed    


  141. PRANGE S, Metereau E, Maillet A, Klinger H, et al
    Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease.
    Mov Disord. 2022 Mar 3. doi: 10.1002/mds.28971.
    PubMed     Abstract available


  142. OLSZEWSKA DA, Lang AE
    The Role of Insular Cortex in Gut-Inflammation Memory: What Does It Mean for Parkinson's Disease?
    Mov Disord. 2022 Mar 1. doi: 10.1002/mds.28975.
    PubMed    


  143. LIN CH, Lin HY, Ho EP, Ke YC, et al
    Reply to: Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
    Mov Disord. 2022;37:665-666.
    PubMed    


  144. SAMBIN S, Menon PJ, Ihle J, Mariani LL, et al
    Down-Regulation of Dopamine Transporter in Early Premotor Phases.
    Mov Disord. 2022;37:663-664.
    PubMed    


  145. LINARD M, Ravier A, Mougue L, Grgurina I, et al
    Infectious Agents as Potential Drivers of alpha-Synucleinopathies.
    Mov Disord. 2022;37:464-477.
    PubMed     Abstract available


  146. ROEDIGER J, Dembek TA, Wenzel G, Butenko K, et al
    StimFit-A Data-Driven Algorithm for Automated Deep Brain Stimulation Programming.
    Mov Disord. 2022;37:574-584.
    PubMed     Abstract available


  147. JANZEN A, Kogan RV, Meles SK, Sittig E, et al
    Rapid Eye Movement Sleep Behavior Disorder: Abnormal Cardiac Image and Progressive Abnormal Metabolic Brain Pattern.
    Mov Disord. 2022;37:624-629.
    PubMed     Abstract available


    February 2022
  148. RAO SC, Sanyaolu AO
    Breaking Barriers: Modeling the Blood-Brain Barrier in Parkinson's Disease Using a Human-Brain-Chip.
    Mov Disord. 2022 Feb 28. doi: 10.1002/mds.28968.
    PubMed    


  149. RASCOL O, Medori R, Baayen C, Such P, et al
    A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.
    Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28970.
    PubMed     Abstract available


  150. KHALIL H, Aldaajani ZF, Aldughmi M, Al-Sharman A, et al
    Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Mov Disord. 2022 Feb 26. doi: 10.1002/mds.28905.
    PubMed     Abstract available


  151. CORNEJO-OLIVAS M, Wu L, Noyce A
    Disruption of Mitochondrial Complex I Induces Progressive Parkinsonism.
    Mov Disord. 2022 Feb 22. doi: 10.1002/mds.28961.
    PubMed    


  152. XING Y, Sapuan AH, Martin-Bastida A, Naidu S, et al
    Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
    Mov Disord. 2022 Feb 15. doi: 10.1002/mds.28934.
    PubMed     Abstract available


  153. LIZARRAGA KJ, Gnanamanogaran B, Al-Ozzi TM, Cohn M, et al
    Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28953.
    PubMed     Abstract available


  154. MAGRINELLI F, Rajapaksha I, Kobylecki C, Latorre A, et al
    Reply to: Juvenile PLA2G6-parkinsonism due to Indian 'Asian' p.R741Q mutation, and response to STN DBS.
    Mov Disord. 2022 Feb 13. doi: 10.1002/mds.28955.
    PubMed    


  155. AYTON S, Hall S, Janelidze S, Kalinowski P, et al
    The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.
    Mov Disord. 2022 Feb 8. doi: 10.1002/mds.28958.
    PubMed     Abstract available


  156. PRASUHN J, Gottlich M, Grosser SS, Reuther K, et al
    In Vivo Brain Sodium Disequilibrium in ATP1A3-Related Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2022 Feb 7. doi: 10.1002/mds.28954.
    PubMed    


  157. MADELUNG CF, Meder D, Fuglsang SA, Marques MM, et al
    Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.
    Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28945.
    PubMed     Abstract available


  158. RAVAT P, Shinde S, Shinde SR, Bangar S, et al
    Juvenile PLA2G6-Parkinsonism Due to Indian 'Asian' p.R741Q Mutation, and Response to STN DBS.
    Mov Disord. 2022 Feb 3. doi: 10.1002/mds.28950.
    PubMed    


  159. SZWEDO AA, Dalen I, Pedersen KF, Camacho M, et al
    GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
    Mov Disord. 2022 Feb 2. doi: 10.1002/mds.28932.
    PubMed     Abstract available


  160. ORTEGA RA, Bodamer O, Peake RWA, Raymond D, et al
    Assessment of Glucocerebrosidase Enzyme Activity in Parkinson Disease Using Multiple Approaches.
    Mov Disord. 2022 Feb 1. doi: 10.1002/mds.28951.
    PubMed    


  161. AAMODT WW, Chen-Plotkin AS
    Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".
    Mov Disord. 2022;37:436-437.
    PubMed    


  162. TODT I, Al-Fatly B, Granert O, Kuhn AA, et al
    The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life.
    Mov Disord. 2022;37:291-301.
    PubMed     Abstract available


  163. D'CRUZ N, Seuthe J, De Somer C, Hulzinga F, et al
    Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait.
    Mov Disord. 2022;37:269-278.
    PubMed     Abstract available


  164. ZIRRA A, Huxford B
    CD4(+) T Cells Contribute to Neurodegeneration in Lewy Body Dementia.
    Mov Disord. 2022;37:268.
    PubMed    


    January 2022
  165. DERKINDEREN P, de Guilhem de Lataillade A, Neunlist M, Rolli-Derkinderen M, et al
    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice through Activating TNF-alpha Pathway.
    Mov Disord. 2022 Jan 31. doi: 10.1002/mds.28948.
    PubMed    


  166. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease.
    Mov Disord. 2022 Jan 29. doi: 10.1002/mds.28936.
    PubMed    


  167. LIU W, Yu Y
    Single-Trajectory Multiple Target for Parkinsonian Mobility and Cognition? An Inadvisable Idea.
    Mov Disord. 2022 Jan 28. doi: 10.1002/mds.28949.
    PubMed    


  168. GLEASON A, Tayebi N, Lopez G, Sidransky E, et al
    No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.
    Mov Disord. 2022 Jan 24. doi: 10.1002/mds.28935.
    PubMed    


  169. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2022 Jan 22. doi: 10.1002/mds.28929.
    PubMed    


  170. GARRIDO A, Santamaria E, Fernandez-Irigoyen J, Soto M, et al
    Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
    Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28927.
    PubMed     Abstract available


  171. SUBRAMANIAN I, Mathur S, Oosterbaan A, Flanagan R, et al
    Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies.
    Mov Disord. 2022 Jan 20. doi: 10.1002/mds.28921.
    PubMed     Abstract available


  172. MURATA H, Barnhill LM, Bronstein JM
    Air Pollution and the Risk of Parkinson's Disease: A Review.
    Mov Disord. 2022 Jan 19. doi: 10.1002/mds.28922.
    PubMed     Abstract available


  173. BUHMANN C, Lezius S, Potter-Nerger M, Gerloff C, et al
    Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD).
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28909.
    PubMed    


  174. COCHEN DE COCK V, Dotov D, Lacombe S, Picot MC, et al
    Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters.
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28894.
    PubMed     Abstract available


  175. VAN DER ZEE S, Kanel P, Gerritsen MJJ, Boertien JM, et al
    Altered Cholinergic Innervation in De Novo Parkinson's Disease with and without Cognitive Impairment.
    Mov Disord. 2022 Jan 17. doi: 10.1002/mds.28913.
    PubMed     Abstract available


  176. MARTINEZ-VALBUENA I, Visanji NP, Olszewska DA, Sousa M, et al
    Combining Skin alpha-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease.
    Mov Disord. 2022 Jan 12. doi: 10.1002/mds.28912.
    PubMed    


  177. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease.
    Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28897.
    PubMed     Abstract available


  178. LEODORI G, De Bartolo MI, Guerra A, Fabbrini A, et al
    Motor Cortical Network Excitability in Parkinson's Disease.
    Mov Disord. 2022 Jan 9. doi: 10.1002/mds.28914.
    PubMed     Abstract available


  179. DOMENIGHETTI C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, et al
    Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.
    Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28902.
    PubMed     Abstract available


  180. VANEGAS-ARROYAVE N, Chen DF, Lauro PM, Norato G, et al
    Where Do Parkinson's Disease Patients Look while Walking?
    Mov Disord. 2022 Jan 8. doi: 10.1002/mds.28917.
    PubMed     Abstract available


  181. MERCHANT K, Sullivan J
    c-Abl Inhibitors as Disease-Modifying Therapies for Parkinson's Disease: Gaps and Opportunities.
    Mov Disord. 2022;37:3-5.
    PubMed    


  182. LA MORGIA C, Romagnoli M, Pizza F, Biscarini F, et al
    Chromatic Pupillometry in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2022;37:205-210.
    PubMed     Abstract available


    December 2021
  183. LEWIS SJG, Factor SA, Giladi N, Hallett M, et al
    Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28837.
    PubMed    


  184. BOHNEN NI, Costa RM, Dauer WT, Factor SA, et al
    Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28883.
    PubMed     Abstract available


  185. GUTTUSO T JR, Sirica D, Tosun D, Zivadinov R, et al
    Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28886.
    PubMed     Abstract available


  186. BOSHKOVSKI T, Cohen-Adad J, Misic B, Arnulf I, et al
    The Myelin-Weighted Connectome in Parkinson's Disease.
    Mov Disord. 2021 Dec 22. doi: 10.1002/mds.28891.
    PubMed     Abstract available


  187. DEVIGNES Q, Bordier C, Viard R, Defebvre L, et al
    Resting-State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease-Mild Cognitive Impairment.
    Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28888.
    PubMed     Abstract available


  188. LIN CH, Lin HY, Ho EP, Ke YC, et al
    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-alpha Pathway.
    Mov Disord. 2021 Dec 17. doi: 10.1002/mds.28890.
    PubMed     Abstract available


  189. ZOLFAGHARI S, Thomann AE, Lewandowski N, Trundell D, et al
    Self-Report versus Clinician Examination in Early Parkinson's Disease.
    Mov Disord. 2021 Dec 13. doi: 10.1002/mds.28884.
    PubMed     Abstract available


  190. BRUNO MK, Watanabe G, Ishikawa K, Chen JJ, et al
    Geographic Variation in Prescription Patterns of Parkinson's Disease Medications.
    Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28880.
    PubMed    


  191. RODRIGUEZ-ROJAS R, Pineda-Pardo JA, Manez-Miro J, Sanchez-Turel A, et al
    Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease.
    Mov Disord. 2021 Dec 3. doi: 10.1002/mds.28862.
    PubMed     Abstract available


  192. MACIAS-GARCIA D, Perinan MT, Munoz-Delgado L, Jesus S, et al
    Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Mov Disord. 2021 Dec 2. doi: 10.1002/mds.28863.
    PubMed    


  193. GHIGLIERI V, Natale G
    Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
    Mov Disord. 2021;36:2979-2980.
    PubMed    


  194. GARCIA AM, Orozco-Arroyave JR
    Reply to: "Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease".
    Mov Disord. 2021;36:2982-2983.
    PubMed    


  195. RUSZ J, Tykalova T
    Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease?
    Mov Disord. 2021;36:2980-2982.
    PubMed    


  196. SUPPA A
    Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation.
    Mov Disord. 2021;36:2979.
    PubMed    


  197. YSSELSTEIN D, Young TJ, Nguyen M, Padmanabhan S, et al
    Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.
    Mov Disord. 2021;36:2719-2730.
    PubMed     Abstract available


  198. VERHAGEN METMAN L, Slavin KV, Rosenow JM, Vitek JL, et al
    More Than Just the Level of Consciousness: Comparing Asleep and Awake Deep Brain Stimulation.
    Mov Disord. 2021;36:2763-2766.
    PubMed    


  199. FOIS AF, Mahant N, Vucic S, Fung VSC, et al
    Measuring Tremor-A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating.
    Mov Disord. 2021;36:2962-2963.
    PubMed    


    November 2021
  200. WERNER MH, Olanow CW
    Parkinson's Disease Modification through Abl Kinase Inhibition: An Opportunity.
    Mov Disord. 2021 Nov 23. doi: 10.1002/mds.28858.
    PubMed     Abstract available


  201. SCAMARCIA PG, Agosta F, Spinelli EG, Basaia S, et al
    Longitudinal White Matter Damage Evolution in Parkinson's Disease.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28864.
    PubMed     Abstract available


  202. SASIKUMAR S, Cohn M, Harmsen IE, Loh A, et al
    Single-Trajectory Multiple-Target Deep Brain Stimulation for Parkinsonian Mobility and Cognition.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28870.
    PubMed     Abstract available


  203. CHEN C, Mossman E, Malko P, McDonald D, et al
    Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease.
    Mov Disord. 2021 Nov 15. doi: 10.1002/mds.28849.
    PubMed     Abstract available


  204. COSENTINO C, Torres L, Velez M, Nunez Y, et al
    SARS-CoV-2 Vaccines and Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2021 Nov 14. doi: 10.1002/mds.28851.
    PubMed    


  205. VOGEL A, Claus I, Ahring S, Gruber D, et al
    Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease.
    Mov Disord. 2021 Nov 13. doi: 10.1002/mds.28854.
    PubMed     Abstract available


  206. LANE EL, Harrison DJ, Ramos-Varas E, Hills R, et al
    Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28856.
    PubMed     Abstract available


  207. SURMEIER DJ, Nguyen JT, Lancki N, Venuto CS, et al
    Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28850.
    PubMed     Abstract available


  208. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
    Mov Disord. 2021 Nov 6. doi: 10.1002/mds.28846.
    PubMed     Abstract available


  209. ARPIN DJ, Mitchell T, Archer DB, Burciu RG, et al
    Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
    Mov Disord. 2021 Nov 1. doi: 10.1002/mds.28838.
    PubMed     Abstract available


  210. LESCHZINER AE, Reck-Peterson SL
    Structural Biology of LRRK2 and its Interaction with Microtubules.
    Mov Disord. 2021;36:2494-2504.
    PubMed     Abstract available


  211. MANOR B, Dagan M, Herman T, Gouskova NA, et al
    Multitarget Transcranial Electrical Stimulation for Freezing of Gait: A Randomized Controlled Trial.
    Mov Disord. 2021;36:2693-2698.
    PubMed     Abstract available


  212. LERCHE S, Sjodin S, Brinkmalm A, Blennow K, et al
    CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB.
    Mov Disord. 2021;36:2595-2604.
    PubMed     Abstract available


  213. BORDERS JC, Sevitz JS, Curtis JA, Vanegas-Arroyave N, et al
    Sensorimotor Cough Dysfunction Is Prevalent and Pervasive in Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2624-2633.
    PubMed     Abstract available


    October 2021
  214. CORVOL JC, Azulay JP, Bosse B, Dauvilliers Y, et al
    THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
    Mov Disord. 2021 Oct 28. doi: 10.1002/mds.28840.
    PubMed     Abstract available


  215. CHARISIS S, Ntanasi E, Stamelou M, Xiromerisiou G, et al
    Plasma Glutathione and Prodromal Parkinson's Disease Probability.
    Mov Disord. 2021 Oct 25. doi: 10.1002/mds.28826.
    PubMed     Abstract available


  216. VAN RENSBURG ZJ, Abrahams S, Chetty D, Step K, et al
    The South African Parkinson's Disease Study Collection.
    Mov Disord. 2021 Oct 22. doi: 10.1002/mds.28828.
    PubMed     Abstract available


  217. SAMBIN S, Lavisse S, Decaix C, Pyatigorskaya N, et al
    Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
    Mov Disord. 2021 Oct 20. doi: 10.1002/mds.28833.
    PubMed    


  218. KLARENDIC M, Kirbis M, Mojsovska E, Kavcic M, et al
    Bee Venom Does Not Reduce the Risk for Parkinson's Disease: Epidemiological Study among Beekeepers.
    Mov Disord. 2021 Oct 16. doi: 10.1002/mds.28820.
    PubMed     Abstract available


  219. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Lower Circulating Lymphocyte Count Predicts ApoE epsilon4-Related Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28799.
    PubMed    


  220. HUXFORD B, Haque T, Joseph AB, Simonet C, et al
    Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28829.
    PubMed    


  221. JARAZO J, Barmpa K, Modamio J, Saraiva C, et al
    Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-beta-Cyclodextrin Treatment.
    Mov Disord. 2021 Oct 12. doi: 10.1002/mds.28810.
    PubMed     Abstract available


  222. SCHIRINZI T, Maftei D, Ralli M, Greco A, et al
    Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28824.
    PubMed    


  223. MAGRINELLI F, Mehta S, Di Lazzaro G, Latorre A, et al
    Dissecting the Phenotype and Genotype of PLA2G6-Related Parkinsonism.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28807.
    PubMed     Abstract available


  224. PU JL, Jin CY, Wang ZX, Fang Y, et al
    Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28805.
    PubMed     Abstract available


  225. PIHLSTROM L, Fan CC, Frei O, Tan M, et al
    Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28808.
    PubMed     Abstract available


  226. JUCAITE A, Cselenyi Z, Kreisl WC, Rabiner EA, et al
    Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [(11) C]PBR28 and Machine Learning Analysis.
    Mov Disord. 2021 Oct 5. doi: 10.1002/mds.28814.
    PubMed     Abstract available


  227. GULER S, Gul T, Guler S, Haerle MC, et al
    Early-Onset Parkinson's Disease: A Novel Deletion Comprising the DJ-1 and TNFRSF9 Genes.
    Mov Disord. 2021 Oct 3. doi: 10.1002/mds.28812.
    PubMed     Abstract available


  228. CAMINITI SP, Carli G, Avenali M, Blandini F, et al
    Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.
    Mov Disord. 2021 Oct 1. doi: 10.1002/mds.28818.
    PubMed     Abstract available


  229. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Reply to: "Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population".
    Mov Disord. 2021;36:2453.
    PubMed    


  230. ONG TL, Dal S, Williams LJ, Morales-Briceno H, et al
    \Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021;36:2452.
    PubMed    


  231. GAN-OR Z, Wood NW
    Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?
    Mov Disord. 2021;36:2220-2222.
    PubMed    


  232. NAMBU A
    Distinct Roles of the Dorsal Versus Ventral Subthalamic Nucleus.
    Mov Disord. 2021;36:2223.
    PubMed    


  233. ERRO R, Mencacci NE, Bhatia KP
    The Emerging Role of Phosphodiesterases in Movement Disorders.
    Mov Disord. 2021;36:2225-2243.
    PubMed     Abstract available


  234. CAMACHO M, Greenland JC, Williams-Gray CH
    The Gastrointestinal Dysfunction Scale for Parkinson's Disease.
    Mov Disord. 2021;36:2358-2366.
    PubMed     Abstract available


    September 2021
  235. REYES-PEREZ P, Bandres-Ciga S
    Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication.
    Mov Disord. 2021 Sep 30. doi: 10.1002/mds.28798.
    PubMed    


  236. MILANOWSKI LM, Oshinaike O, Walton RL, Soto-Beasley AI, et al
    Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease.
    Mov Disord. 2021 Sep 29. doi: 10.1002/mds.28803.
    PubMed    


  237. EVIDENTE VGH, Evidente DH, Ortega SC, Levine TD, et al
    X-Linked Dystonia-Parkinsonism ("Lubag") May Present with Peripheral Synucleinopathy.
    Mov Disord. 2021 Sep 28. doi: 10.1002/mds.28801.
    PubMed     Abstract available


  238. REN Y, Jiang H, Pu J, Li L, et al
    Molecular Features of Parkinson's Disease in Patient-Derived Midbrain Dopaminergic Neurons.
    Mov Disord. 2021 Sep 26. doi: 10.1002/mds.28786.
    PubMed     Abstract available


  239. BUCHANAN SM, Richards M, Schott JM, Schrag A, et al
    Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations.
    Mov Disord. 2021 Sep 25. doi: 10.1002/mds.28777.
    PubMed     Abstract available


  240. MAASS F, Michalke B, Willkommen D, Canaslan S, et al
    Cerebrospinal Fluid Iron-Ferritin Ratio as a Potential Progression Marker for Parkinson's Disease.
    Mov Disord. 2021 Sep 23. doi: 10.1002/mds.28790.
    PubMed     Abstract available


  241. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2021 Sep 22. doi: 10.1002/mds.28792.
    PubMed     Abstract available


  242. LAKE J, Reed X, Langston RG, Nalls MA, et al
    Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
    Mov Disord. 2021 Sep 20. doi: 10.1002/mds.28787.
    PubMed     Abstract available


  243. RENNER H, Scholer HR, Bruder JM
    Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28775.
    PubMed     Abstract available


  244. POEWE W, Stocchi F, Arkadir D, Ebersbach G, et al
    Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28758.
    PubMed     Abstract available


  245. MAILLET A, Metereau E, Tremblay L, Favre E, et al
    Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28722.
    PubMed     Abstract available


  246. AAMODT WW, Waligorska T, Shen J, Tropea TF, et al
    Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
    Mov Disord. 2021 Sep 4. doi: 10.1002/mds.28779.
    PubMed     Abstract available


  247. LIN ZH, Zhang BR
    Striking While the Iron is Hot: The Role of Prosaposin (PSAP) in Parkinson's Disease.
    Mov Disord. 2021 Sep 3. doi: 10.1002/mds.28781.
    PubMed    


  248. ELSAYED I, Foote IF
    Improving Diversity in Parkinson's Disease Genetics: Findings from the First-Ever Genome-Wide Association Study in Latinos.
    Mov Disord. 2021 Sep 2. doi: 10.1002/mds.28782.
    PubMed    


  249. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Reply to: "Is Conscientiousness Related to the Risk of Parkinson's Disease?"
    Mov Disord. 2021;36:2216.
    PubMed    


  250. LUCA A, Nicoletti A, Zappia M
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021;36:2215.
    PubMed    


  251. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy".
    Mov Disord. 2021;36:2208-2209.
    PubMed    


  252. LIU H, Koros C, Stefanis L, Gasser T, et al
    Reply to: "alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism".
    Mov Disord. 2021;36:2212-2213.
    PubMed    


  253. RAU A, Jost WH, von der Warth R, Urbach H, et al
    Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2207-2208.
    PubMed    


  254. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Parkinson's Disease.
    Mov Disord. 2021;36:2217.
    PubMed    


  255. SOKRATOUS M, Breza M, Senkevich K, Gan-Or Z, et al
    alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism.
    Mov Disord. 2021;36:2209-2212.
    PubMed    


  256. ISHIMOTO T, Yamakado H
    Membranes and Organelle in Lewy Bodies: The Mastermind or the Bystander?
    Mov Disord. 2021;36:2026.
    PubMed    


  257. MAJBOUR NK, Abdi IY, Dakna M, Wicke T, et al
    Cerebrospinal alpha-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Mov Disord. 2021;36:2048-2056.
    PubMed     Abstract available


  258. ANDERSEN KB, Hansen AK, Damholdt MF, Horsager J, et al
    Reduced Synaptic Density in Patients with Lewy Body Dementia: An [(11) C]UCB-J PET Imaging Study.
    Mov Disord. 2021;36:2057-2065.
    PubMed     Abstract available


    August 2021
  259. LIU Y, Lawton MA, Lo C, Bowring F, et al
    Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study.
    Mov Disord. 2021 Aug 26. doi: 10.1002/mds.28763.
    PubMed     Abstract available


  260. KAINAGA M, Shirota Y, Kodama S, Toda T, et al
    Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson's Disease: An Observational Study.
    Mov Disord. 2021 Aug 25. doi: 10.1002/mds.28766.
    PubMed    


  261. ONOFRJ M, Di Iorio A, Carrarini C, Russo M, et al
    Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease.
    Mov Disord. 2021 Aug 24. doi: 10.1002/mds.28745.
    PubMed     Abstract available


  262. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach.
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28760.
    PubMed     Abstract available


  263. CAMPESE N, Goebel G, Leys F, Ndayisaba JP, et al
    Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28768.
    PubMed    


  264. O'SHEA SA, Hickman RA, Cortes E, Vonsattel JP, et al
    Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1.
    Mov Disord. 2021 Aug 20. doi: 10.1002/mds.28756.
    PubMed     Abstract available


  265. CIRNARU MD, Creus-Muncunill J, Nelson S, Lewis T, et al
    Striatal Cholinergic Dysregulation after Neonatal Decrease in X-Linked Dystonia Parkinsonism-Related TAF1 Isoforms.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28750.
    PubMed     Abstract available


  266. SIA MW, Foo JN, Saffari SE, Wong AS, et al
    Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28761.
    PubMed     Abstract available


  267. QI S, Yin P, Wang L, Qu M, et al
    Prevalence of Parkinson's Disease: A Community-Based Study in China.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28762.
    PubMed     Abstract available


  268. GARCIA AM, Arias-Vergara T, C Vasquez-Correa J, Noth E, et al
    Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28751.
    PubMed     Abstract available


  269. LE HERON C, MacAskill M, Mason D, Dalrymple-Alford J, et al
    A Multi-Step Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2021 Aug 10. doi: 10.1002/mds.28719.
    PubMed     Abstract available


  270. ERRO R, Buonomo AR, Barone P, Pellecchia MT, et al
    Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson Disease.
    Mov Disord. 2021 Aug 9. doi: 10.1002/mds.28772.
    PubMed    


  271. OLANOW CW, Poewe W, Rascol O, Stocchi F, et al
    On-Demand Therapy for OFF Episodes in Parkinson's Disease.
    Mov Disord. 2021 Aug 7. doi: 10.1002/mds.28726.
    PubMed     Abstract available


  272. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28723.
    PubMed     Abstract available


  273. OKUNOYE O, Horsfall L, Marston L, Walters K, et al
    Mortality of People with Parkinson's Disease in a Large UK-Based Cohort Study: Time Trends and Relationship to Disease Duration.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28727.
    PubMed     Abstract available


  274. MARKAKI I, Ntetsika T, Svenningsson P
    Reply to: "HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study".
    Mov Disord. 2021;36:1993.
    PubMed    


  275. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Reply to: Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994-1995.
    PubMed    


  276. TORRES L, Velez M, Suarez R, Nunez Y, et al
    Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994.
    PubMed    


  277. ZITTEL S, Uyar M, Lezius S, Gerloff C, et al
    HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study.
    Mov Disord. 2021;36:1991-1992.
    PubMed    


  278. ZECH M, Jech R, Boesch S, Skorvanek M, et al
    Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.
    Mov Disord. 2021;36:1959-1964.
    PubMed     Abstract available


  279. KOSS DJ, Campesan S, Giorgini F, Outeiro TF, et al
    Dysfunction of RAB39B-Mediated Vesicular Trafficking in Lewy Body Diseases.
    Mov Disord. 2021;36:1744-1758.
    PubMed     Abstract available


  280. FASANO A, Gurevich T, Jech R, Kovacs N, et al
    Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
    Mov Disord. 2021;36:1853-1862.
    PubMed     Abstract available


  281. KIM R, Lee JY, Kim YK, Kim H, et al
    Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder-Related Metabolic Pattern Expression.
    Mov Disord. 2021;36:1889-1898.
    PubMed     Abstract available


    July 2021
  282. REN X, Lin J, Stebbins GT, Goetz CG, et al
    Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.
    Mov Disord. 2021 Jul 30. doi: 10.1002/mds.28730.
    PubMed     Abstract available


  283. LAANSMA MA, Bright JK, Al-Bachari S, Anderson TJ, et al
    International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
    Mov Disord. 2021 Jul 20. doi: 10.1002/mds.28706.
    PubMed     Abstract available


  284. SARASSO E, Agosta F, Piramide N, Gardoni A, et al
    Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study.
    Mov Disord. 2021 Jul 19. doi: 10.1002/mds.28717.
    PubMed     Abstract available


  285. GROS P, Wang X, Guan J, Lang AE, et al
    Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.
    Mov Disord. 2021 Jul 9. doi: 10.1002/mds.28712.
    PubMed     Abstract available


  286. CONCHA-MARAMBIO L, Farris CM, Holguin B, Ma Y, et al
    Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28715.
    PubMed    


  287. FREIRE-ALVAREZ E, Kurca E, Lopez Manzanares L, Pekkonen E, et al
    Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28703.
    PubMed     Abstract available


  288. MULLER-NEDEBOCK AC, Komolafe MA, Fawale MB, Carr JA, et al
    Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa.
    Mov Disord. 2021 Jul 6. doi: 10.1002/mds.28710.
    PubMed    


  289. SCHILLING M, Lill CM
    MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression.
    Mov Disord. 2021 Jul 5. doi: 10.1002/mds.28700.
    PubMed    


  290. CHOONG CJ, Kimura Y, Mochizuki H
    Disturbed Mitochondria-Lysosome Crosstalk in GBA1-Associated Parkinson's Disease.
    Mov Disord. 2021 Jul 1. doi: 10.1002/mds.28693.
    PubMed    


  291. RASCOL O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, et al
    Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
    Mov Disord. 2021;36:1704-1711.
    PubMed     Abstract available


  292. SHILL HA, Zhang N, Driver-Dunckley E, Mehta S, et al
    Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:1700-1704.
    PubMed     Abstract available


  293. PERKINS JE, Janzen A, Bernhard FP, Wilhelm K, et al
    Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1720-1726.
    PubMed     Abstract available


  294. DE ALMEIDA CMO, Brito MMC, Bosaipo NB, Pimentel AV, et al
    Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1711-1715.
    PubMed     Abstract available


  295. WITTKE C, Petkovic S, Dobricic V, Schaake S, et al
    Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
    Mov Disord. 2021;36:1499-1510.
    PubMed     Abstract available


    June 2021
  296. VIDENOVIC A, Amara AW, Comella C, Schweitzer PK, et al
    Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Mov Disord. 2021 Jun 30. doi: 10.1002/mds.28702.
    PubMed     Abstract available


  297. PATEL SG, Buchanan CM, Mulroy E, Simpson M, et al
    Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.
    Mov Disord. 2021 Jun 22. doi: 10.1002/mds.28665.
    PubMed    


  298. FIORENZATO E, Antonini A, Bisiacchi P, Weis L, et al
    Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Jun 14. doi: 10.1002/mds.28682.
    PubMed     Abstract available


  299. NIGAM M, Ayadi I, Noiray C, Branquino-Bras AC, et al
    Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28692.
    PubMed     Abstract available


  300. GELPI E, Haberler C, Micko A, Polt A, et al
    Focal Subthalamic Atrophy After Long-Term Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28653.
    PubMed    


  301. MAITI B, Rawson KS, Tanenbaum AB, Koller JM, et al
    Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease.
    Mov Disord. 2021 Jun 10. doi: 10.1002/mds.28684.
    PubMed     Abstract available


  302. MUNOZ-DELGADO L, Macias-Garcia D, Jesus S, Martin-Rodriguez JF, et al
    Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease.
    Mov Disord. 2021 Jun 8. doi: 10.1002/mds.28685.
    PubMed     Abstract available


  303. SEGER AD, Farrher E, Doppler CEJ, Gogishvili A, et al
    Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
    Mov Disord. 2021 Jun 7. doi: 10.1002/mds.28674.
    PubMed     Abstract available


  304. HAMID E, Ayele BA, Massi DG, Ben Sassi S, et al
    Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
    Mov Disord. 2021 Jun 3. doi: 10.1002/mds.28669.
    PubMed     Abstract available


  305. ISONAKA R, Goldstein DS, Zhu W, Yoon E, et al
    alpha-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
    Mov Disord. 2021 Jun 2. doi: 10.1002/mds.28667.
    PubMed     Abstract available


  306. MATHUR S
    Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients.
    Mov Disord. 2021;36:1290-1292.
    PubMed    


    May 2021
  307. CARVALHO V, Ferreira JJ, Correia Guedes L
    Tremor and Parkinsonism in Chromosomopathies - A Systematic Review.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28663.
    PubMed     Abstract available


  308. CONEYS R, Storm CS, Kia DA, Almramhi M, et al
    Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28662.
    PubMed     Abstract available


  309. FEARON C, Mikulis DJ, Lang AE
    Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28656.
    PubMed    


  310. BOUALI-BENAZZOUZ R, Benazzouz A
    Covid-19 Infection and Parkinsonism: Is There a Link?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28680.
    PubMed     Abstract available


  311. ORSO B, Arnaldi D, Girtler N, Brugnolo A, et al
    Dopaminergic and Serotonergic Degeneration and Cortical [(18) F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28654.
    PubMed     Abstract available


  312. DEAN DN, Lee JC
    Linking Parkinson's Disease and Melanoma: Interplay Between alpha-Synuclein and Pmel17 Amyloid Formation.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28655.
    PubMed     Abstract available


  313. SCHWEDHELM E, Englisch C, Niemann L, Lezius S, et al
    Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD).
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28652.
    PubMed     Abstract available


  314. TOFFOLI M, Higgins A, Lee C, Koletsi S, et al
    Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28616.
    PubMed     Abstract available


  315. STUENDL A, Kraus T, Chatterjee M, Zapke B, et al
    alpha-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28639.
    PubMed     Abstract available


  316. O'SULLIVAN JM, den Heijer JM, Groeneveld GJ, Cooper AA, et al
    Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28620.
    PubMed    


  317. HAN F, Brown GL, Zhu Y, Belkin-Rosen AE, et al
    Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
    Mov Disord. 2021 May 17. doi: 10.1002/mds.28643.
    PubMed     Abstract available


  318. MORLEY D, Dummett S, Kelly L, Jenkinson C, et al
    Development of an Exercise-Specific Parkinson's Disease Questionnaire: The PDQ-Exercise.
    Mov Disord. 2021 May 15. doi: 10.1002/mds.28644.
    PubMed     Abstract available


  319. MARRAS C, Mills KA, Eberly S, Oakes D, et al
    Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients With Early Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28641.
    PubMed     Abstract available


  320. RICCIARDI L, Fischer P, Mostofi A, Tinkhauser G, et al
    Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28625.
    PubMed     Abstract available


  321. ESTIAR MA, Senkevich K, Yu E, Varghaei P, et al
    Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28640.
    PubMed     Abstract available


  322. COLLOBY SJ, Nathan PJ, Bakker G, Lawson RA, et al
    Spatial Covariance of Cholinergic Muscarinic M1 /M4 Receptors in Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28564.
    PubMed     Abstract available


  323. NAITO T, Satake W, Ogawa K, Suzuki K, et al
    Trans-Ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28583.
    PubMed     Abstract available


  324. BARBUTI PA, Barker RA, Brundin P, Przedborski S, et al
    Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
    Mov Disord. 2021 May 8. doi: 10.1002/mds.28628.
    PubMed     Abstract available


  325. IWAKI H, Leonard HL, Makarious MB, Bookman M, et al
    Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28549.
    PubMed     Abstract available


  326. DI LAZZARO G, Magrinelli F, Estevez-Fraga C, Valente EM, et al
    X-Linked Parkinsonism: Phenotypic and Genetic Heterogeneity.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28565.
    PubMed     Abstract available


  327. MCINTOSH E, Kent S, Gray A, Clarke CE, et al
    Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28623.
    PubMed     Abstract available


  328. MIRELMAN A, Ben Or Frank M, Melamed M, Granovsky L, et al
    Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28631.
    PubMed     Abstract available


  329. KAASINEN V, Vahlberg T, Stoessl AJ, Strafella AP, et al
    Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28632.
    PubMed     Abstract available


  330. KREMER T, Taylor KI, Siebourg-Polster J, Gerken T, et al
    Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28608.
    PubMed     Abstract available


  331. SCHERBAUM R, Kwon EH, Richter D, Bartig D, et al
    Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28586.
    PubMed     Abstract available


  332. MESTRE TA, Macklin EA, Ascherio A, Ferreira JJ, et al
    Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28630.
    PubMed     Abstract available


  333. SCOTT GD, Lim MM, Drake MG, Woltjer R, et al
    Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans.
    Mov Disord. 2021 May 3. doi: 10.1002/mds.28636.
    PubMed     Abstract available


  334. KIEBURTZ K, Olanow CW
    Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".
    Mov Disord. 2021;36:1281-1282.
    PubMed    


  335. SIMON DK
    A New Approach to the Development of Disease-Modifying Therapies for PD.
    Mov Disord. 2021;36:1281.
    PubMed    


  336. LERCHE S, Schulte C, Wurster I, Machetanz G, et al
    The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA.
    Mov Disord. 2021;36:1216-1228.
    PubMed     Abstract available


    April 2021
  337. YILMAZ R, Suenkel U, Postuma RB, Heinzel S, et al
    Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies.
    Mov Disord. 2021 Apr 30. doi: 10.1002/mds.28637.
    PubMed    


  338. SARANZA G, Villanueva EQ 3rd, Lang AE
    Preferences for Communication About End-of-Life Care in Atypical Parkinsonism.
    Mov Disord. 2021 Apr 28. doi: 10.1002/mds.28633.
    PubMed     Abstract available


  339. HUYNH B, Fu Y, Kirik D, Shine JM, et al
    Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
    Mov Disord. 2021 Apr 26. doi: 10.1002/mds.28615.
    PubMed     Abstract available


  340. TSUNEMI T, Oyama G, Saiki S, Hatano T, et al
    Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Mov Disord. 2021 Apr 25. doi: 10.1002/mds.28595.
    PubMed     Abstract available


  341. LETA V, Rodriguez-Violante M, Abundes A, Rukavina K, et al
    Parkinson's disease and Post-COVID-19 syndrome: The Parkinson's Long-COVID spectrum.
    Mov Disord. 2021 Apr 22. doi: 10.1002/mds.28622.
    PubMed    


  342. LI C, Ou R, Chen Y, Gu X, et al
    Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study.
    Mov Disord. 2021 Apr 21. doi: 10.1002/mds.28621.
    PubMed     Abstract available


  343. CHEN Y, Wu W, Zhao S, Lv X, et al
    Increased Accumulation of alpha-Synuclein in Inflamed Appendices of Parkinson's Disease Patients.
    Mov Disord. 2021 Apr 20. doi: 10.1002/mds.28553.
    PubMed     Abstract available


  344. JOHNSON LA, Aman JE, Yu Y, Escobar Sanabria D, et al
    High-Frequency Oscillations in the Pallidum: A Pathophysiological Biomarker in Parkinson's Disease?
    Mov Disord. 2021 Apr 13. doi: 10.1002/mds.28566.
    PubMed     Abstract available


  345. SOARES C, Carneiro DR, Dias R, Ferreira D, et al
    Behind the mask: recognizing facial features of Parkinson's disease during the COVID-19 pandemic.
    Mov Disord. 2021 Apr 9. doi: 10.1002/mds.28619.
    PubMed    


  346. ZAHED H, Zuzuarregui JRP, Gilron R, Denison T, et al
    The Neurophysiology of Sleep in Parkinson's Disease.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28562.
    PubMed     Abstract available


  347. LIM SH, Ferdousi M, Kalteniece A, Mahfoud ZR, et al
    Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28602.
    PubMed     Abstract available


  348. JIANG C, Hopfner F, Berg D, Hu MT, et al
    Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28591.
    PubMed     Abstract available


  349. KOOHI N, Bancroft MJ, Patel J, Castro P, et al
    Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations.
    Mov Disord. 2021 Apr 6. doi: 10.1002/mds.28609.
    PubMed    


  350. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28575.
    PubMed     Abstract available


  351. UEDA J, Uemura N, Sawamura M, Taguchi T, et al
    Perampanel Inhibits alpha-Synuclein Transmission in Parkinson's Disease Models.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28558.
    PubMed     Abstract available


  352. NIJHUIS FAP, Esselink R, de Bie RMA, Groenewoud H, et al
    Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
    Mov Disord. 2021 Apr 2. doi: 10.1002/mds.28599.
    PubMed     Abstract available


  353. HELMICH RC, Van den Berg KRE, Panyakaew P, Cho HJ, et al
    Cerebello-Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease.
    Mov Disord. 2021 Apr 1. doi: 10.1002/mds.28603.
    PubMed    


  354. GUTTLER C, Nikulin VV, van Riesen C
    Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
    Mov Disord. 2021;36:1045-1047.
    PubMed    


  355. SCHMIDT SL, Grill WM
    Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2021;36:1044-1045.
    PubMed    


  356. NEUMANN WJ, Rodriguez-Oroz MC
    Machine Learning Will Extend the Clinical Utility of Adaptive Deep Brain Stimulation.
    Mov Disord. 2021;36:796-799.
    PubMed    


  357. RUSZ J, Tykalova T, Ramig LO, Tripoliti E, et al
    Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders.
    Mov Disord. 2021;36:803-814.
    PubMed     Abstract available


  358. GEORGIEV D, Roskar S, Cus A, Wilkinson L, et al
    STN-DBS Increases Proactive but Not Retroactive Interference During Verbal Learning in PD.
    Mov Disord. 2021;36:1010-1015.
    PubMed     Abstract available


  359. OSHIMA S, Fushimi Y, Okada T, Nakajima S, et al
    Neuromelanin-Sensitive Magnetic Resonance Imaging Using DANTE Pulse.
    Mov Disord. 2021;36:874-882.
    PubMed     Abstract available


  360. BOOTH S, Ramadan A, Zhang D, Lu L, et al
    The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
    Mov Disord. 2021;36:938-947.
    PubMed     Abstract available


    March 2021
  361. VISANJI NP, Lang AE
    Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28590.
    PubMed    


  362. KLUGER BM, Dolhun R, Sumrall M, Hall K, et al
    Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28556.
    PubMed    


  363. SCHIESS M, Suescun J, Doursout MF, Adams C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
    Mov Disord. 2021 Mar 27. doi: 10.1002/mds.28582.
    PubMed     Abstract available


  364. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021 Mar 25. doi: 10.1002/mds.28594.
    PubMed     Abstract available


  365. GROVER S, Kumar-Sreelatha AA, Bobbili DR, May P, et al
    Replication of a Novel Parkinson's Locus in a European Ancestry Population.
    Mov Disord. 2021 Mar 24. doi: 10.1002/mds.28546.
    PubMed     Abstract available


  366. ABRAHAM DS, Pham Nguyen TP, Willis AW
    Claims-Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease.
    Mov Disord. 2021 Mar 23. doi: 10.1002/mds.28561.
    PubMed     Abstract available


  367. YAO CW, Saha-Chaudhuri P, Zolfaghari S, Pelletier A, et al
    Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population-Based CLSA.
    Mov Disord. 2021 Mar 22. doi: 10.1002/mds.28571.
    PubMed    


  368. SALARI M, Etemadifar M, Zali A, Medghalchi A, et al
    Seroprevalence of SARS-CoV-2 in Parkinson's Disease Patients: A Case-Control Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28580.
    PubMed    


  369. MARINI K, Seppi K, Tschiderer L, Kiechl S, et al
    Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28570.
    PubMed    


  370. CANONICO M, Pesce G, Bonaventure A, Le Noan-Laine M, et al
    Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy.
    Mov Disord. 2021 Mar 16. doi: 10.1002/mds.28563.
    PubMed     Abstract available


  371. DOBKIN RD, Mann SL, Weintraub D, Rodriguez KM, et al
    Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment.
    Mov Disord. 2021 Mar 12. doi: 10.1002/mds.28548.
    PubMed     Abstract available


  372. GAURAV R, Yahia-Cherif L, Pyatigorskaya N, Mangone G, et al
    Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Mov Disord. 2021 Mar 10. doi: 10.1002/mds.28531.
    PubMed     Abstract available


  373. CHOHAN H, Senkevich K, Patel RK, Bestwick JP, et al
    Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
    Mov Disord. 2021 Mar 8. doi: 10.1002/mds.28551.
    PubMed     Abstract available


  374. DUYSENS J, Nonnekes J
    Parkinson's Kinesia Paradoxa Is Not a Paradox.
    Mov Disord. 2021 Mar 3. doi: 10.1002/mds.28550.
    PubMed    


  375. CLAUS I, Muhle P, Czechowski J, Ahring S, et al
    Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease.
    Mov Disord. 2021 Mar 2. doi: 10.1002/mds.28552.
    PubMed     Abstract available


  376. FEARON C, Lang AE, Espay AJ
    The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes.
    Mov Disord. 2021;36:594-598.
    PubMed    


  377. BORGHAMMER P, Horsager J
    The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes.
    Mov Disord. 2021;36:785-786.
    PubMed    


  378. FEARON C, Lang AE, J Espay A
    Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes".
    Mov Disord. 2021;36:786-787.
    PubMed    


  379. SARTER M, Avila C, Kucinski A, Donovan E, et al
    Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.
    Mov Disord. 2021;36:535-546.
    PubMed     Abstract available


  380. YOUNCE JR, Campbell MC, Hershey T, Tanenbaum AB, et al
    Resting-State Functional Connectivity Predicts STN DBS Clinical Response.
    Mov Disord. 2021;36:662-671.
    PubMed     Abstract available


  381. POLISSIDIS A, Koronaiou M, Kollia V, Koronaiou E, et al
    Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human alpha-Synuclein BAC Transgenic Rats.
    Mov Disord. 2021;36:716-728.
    PubMed     Abstract available


  382. HANSS Z, Larsen SB, Antony P, Mencke P, et al
    Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
    Mov Disord. 2021;36:704-715.
    PubMed     Abstract available


    February 2021
  383. DE MICCO R, Agosta F, Basaia S, Siciliano M, et al
    Functional Connectomics and Disease Progression in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28541.
    PubMed     Abstract available


  384. BURTSCHER J, Syed MMK, Lashuel HA, Millet GP, et al
    Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28544.
    PubMed     Abstract available


  385. MARKAKI I, Ntetsika T, Sorjonen K, Svenningsson P, et al
    Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28545.
    PubMed     Abstract available


  386. CHAHINE LM, Zhu X, Ehrenkranz R, Chen H, et al
    Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28535.
    PubMed    


  387. KAKAR RS, Pastor JV, Moe OW, Ambrosio F, et al
    Peripheral Klotho and Parkinson's Disease.
    Mov Disord. 2021 Feb 25. doi: 10.1002/mds.28530.
    PubMed    


  388. MOONEN AJH, Mulders AEP, Defebvre L, Duits A, et al
    Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28533.
    PubMed     Abstract available


  389. AVENALI M, Cerri S, Ongari G, Ghezzi C, et al
    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28496.
    PubMed     Abstract available


  390. LIU H, Koros C, Strohaker T, Schulte C, et al
    A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28534.
    PubMed     Abstract available


  391. SONG S, Luo Z, Li C, Huang X, et al
    Changes in Body Composition Before and After Parkinson's Disease Diagnosis.
    Mov Disord. 2021 Feb 22:e28536. doi: 10.1002/mds.28536.
    PubMed     Abstract available


  392. AEED F, Cermak N, Schiller J, Schiller Y, et al
    Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2021 Feb 19. doi: 10.1002/mds.28538.
    PubMed     Abstract available


  393. KLEINER G, Fernandez HH, Chou KL, Fasano A, et al
    Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire.
    Mov Disord. 2021 Feb 15. doi: 10.1002/mds.28507.
    PubMed     Abstract available


  394. GALPER J, Balwani M, Fahn S, Waters C, et al
    Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers With and Without Parkinson Disease.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28525.
    PubMed     Abstract available


  395. BRIGHT JM, Carlisle HJ, Toda AMA, Murphy M, et al
    Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28490.
    PubMed     Abstract available


  396. PAZ RM, Tubert C, Stahl AM, Amarillo Y, et al
    Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
    Mov Disord. 2021 Feb 6. doi: 10.1002/mds.28516.
    PubMed     Abstract available


  397. ANTAR T, Iwaki H, B Singleton A
    Reply to: 'Letter to the Editor on "Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities"'.
    Mov Disord. 2021;36:527-528.
    PubMed    


  398. OUTEIRO TF, Krisko A
    Reply to: "Parkinson's Disease and COVID-19: Do We Need to Be More Patient?"
    Mov Disord. 2021;36:278-279.
    PubMed    


  399. GONZALEZ-LATAPI P, Fearon C, Fasano A, Lang AE, et al
    Parkinson's Disease and COVID-19: Do We Need to Be More Patient?
    Mov Disord. 2021;36:277.
    PubMed    


  400. DE LA ROSA T, Amado Scerni D, Scorza FA
    Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities.
    Mov Disord. 2021;36:526.
    PubMed    


  401. HO GPH, Ramalingam N, Imberdis T, Wilkie EC, et al
    Upregulation of Cellular Palmitoylation Mitigates alpha-Synuclein Accumulation and Neurotoxicity.
    Mov Disord. 2021;36:348-359.
    PubMed     Abstract available


    January 2021
  402. MULLER-NEDEBOCK AC, van der Westhuizen FH, Koks S, Bardien S, et al
    Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28475.
    PubMed     Abstract available


  403. JEONG SH, Lee HS, Jung JH, Baik K, et al
    White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28510.
    PubMed     Abstract available



  404. GP2: The Global Parkinson's Genetics Program.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28494.
    PubMed    


  405. KIM JJ, Makarious MB, Bandres-Ciga S, Gibbs JR, et al
    The Parkinson's Disease DNA Variant Browser.
    Mov Disord. 2021 Jan 26. doi: 10.1002/mds.28488.
    PubMed     Abstract available


  406. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28462.
    PubMed     Abstract available


  407. DONAHUE EK, Murdos A, Jakowec MW, Sheikh-Bahaei N, et al
    Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28473.
    PubMed     Abstract available


  408. WELTON T, Tan EK
    Applying Artificial Intelligence to Multi-Omic Data: New Functional Variants in Parkinson's Disease.
    Mov Disord. 2021 Jan 17. doi: 10.1002/mds.28481.
    PubMed    


  409. MICHELI F, Vissani M, Pecchioli G, Terenzi F, et al
    Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity.
    Mov Disord. 2021 Jan 16. doi: 10.1002/mds.28497.
    PubMed     Abstract available


  410. AVRAM CM, Brumbach BH, Hiller AL
    A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28471.
    PubMed     Abstract available


  411. LIN CH, Chang CH, Tai CH, Cheng MF, et al
    A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28474.
    PubMed     Abstract available


  412. RAVANIDIS S, Bougea A, Karampatsi D, Papagiannakis N, et al
    Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 12. doi: 10.1002/mds.28467.
    PubMed     Abstract available


  413. HERZ DM, Meder D, Camilleri JA, Eickhoff SB, et al
    Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28468.
    PubMed     Abstract available


  414. VILA-VICOSA D, Clemente A, Pona-Ferreira F, Leitao M, et al
    Unsupervised walking activity assessment reveals COVID-19 impact on Parkinson's disease patients.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28514.
    PubMed    


  415. ZARKALI A, McColgan P, Leyland LA, Lees AJ, et al
    Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
    Mov Disord. 2021 Jan 9. doi: 10.1002/mds.28477.
    PubMed     Abstract available


  416. KUUSIMAKI T, Al-Abdulrasul H, Kurki S, Hietala J, et al
    Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28484.
    PubMed     Abstract available


  417. CHEN L, Bedard P, Hallett M, Horovitz SG, et al
    Dynamics of Top-Down Control and Motor Networks in Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28461.
    PubMed     Abstract available


  418. SCHIRINZI T, Maftei D, Pieri M, Bernardini S, et al
    Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28458.
    PubMed    


  419. METCALFE-ROACH A, Yu AC, Golz E, Cirstea M, et al
    MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28464.
    PubMed     Abstract available


  420. BAUMGARTNER AJ, Press DZ, Simon DK
    The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28483.
    PubMed    


  421. CHOE CU, Potter-Nerger M, Buhmann C, Blankenberg S, et al
    Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease".
    Mov Disord. 2021;36:273-274.
    PubMed    


  422. TRILCK-WINKLER M, Borsche M, Konig IR, Balck A, et al
    Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
    Mov Disord. 2021;36:271-273.
    PubMed    


  423. WITT K
    The Impact of the Basal Ganglia on Working Memory: Evidence from Parkinson's Disease.
    Mov Disord. 2021;36:13-15.
    PubMed    


  424. FULLER RLM, Sanchez-Ferro A, Goetz CG, Martinez-Martin P, et al
    In Support of Electronic Versions of Movement Disorder Society Rating Scales.
    Mov Disord. 2021;36:270-271.
    PubMed    


  425. TURNER TH, Dale ML
    Reply to: "In Support of Electronic Versions of Movement Disorder Society Rating Scales".
    Mov Disord. 2021;36:271.
    PubMed    


  426. SARANZA G, Lang AE
    Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
    Mov Disord. 2021;36:265-266.
    PubMed    


  427. KIEBURTZ K, Katz R, McGarry A, Olanow CW, et al
    A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
    Mov Disord. 2021;36:59-63.
    PubMed     Abstract available


  428. VIEIRA-YANO B, Martini DN, Horak FB, de Lima-Pardini A, et al
    The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity.
    Mov Disord. 2021;36:152-163.
    PubMed     Abstract available


    December 2020
  429. WILSON J, Yarnall AJ, Craig CE, Galna B, et al
    Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Mov Disord. 2020 Dec 31. doi: 10.1002/mds.28453.
    PubMed     Abstract available


  430. DUITS AA, Boots LMM, Mulders AEP, Moonen AJH, et al
    Covid Proof Self-Management Training for Caregivers of Patients with Parkinson's Disease.
    Mov Disord. 2020 Dec 27. doi: 10.1002/mds.28457.
    PubMed    


  431. FILIPPOU P, Outeiro TF
    Cancer and Parkinson's Disease: Common Targets, Emerging Hopes.
    Mov Disord. 2020 Dec 21. doi: 10.1002/mds.28425.
    PubMed     Abstract available


  432. NISSEN SK, Ferreira SA, Nielsen MC, Schulte C, et al
    Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
    Mov Disord. 2020 Dec 17. doi: 10.1002/mds.28424.
    PubMed     Abstract available


  433. ZOON TJC, van Rooijen G, Balm GMFC, Bergfeld IO, et al
    Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2020 Dec 16. doi: 10.1002/mds.28390.
    PubMed     Abstract available


  434. SKRAHINA V, Gaber H, Vollstedt EJ, Forster TM, et al
    The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28416.
    PubMed     Abstract available


  435. KLINE EM, Houser MC, Herrick MK, Seibler P, et al
    Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28411.
    PubMed     Abstract available


  436. ELFIL M, Bahbah EI, Attia MM, Eldokmak M, et al
    Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease.
    Mov Disord. 2020 Dec 9. doi: 10.1002/mds.28412.
    PubMed     Abstract available


  437. MULLIN S, Stokholm MG, Hughes D, Mehta A, et al
    Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.
    Mov Disord. 2020 Dec 5. doi: 10.1002/mds.28375.
    PubMed     Abstract available


  438. CAREY G, Gormezoglu M, de Jong JJA, Hofman PAM, et al
    Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2020 Dec 2. doi: 10.1002/mds.28404.
    PubMed     Abstract available


  439. OLSZEWSKA DA, Lang AE
    "Opening" New Insights Into LRRK2 Conformation and the Microtubule.
    Mov Disord. 2020;35:2162-2163.
    PubMed    


    November 2020
  440. MARTIN WRW, Miles M, Zhong Q, Hartlein J, et al
    Is Levodopa Response a Valid Indicator of Parkinson's Disease?
    Mov Disord. 2020 Nov 30. doi: 10.1002/mds.28406.
    PubMed     Abstract available


  441. GUTTLER C, Altschuler J, Tanev K, Bockmann S, et al
    Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2020 Nov 28. doi: 10.1002/mds.28403.
    PubMed     Abstract available


  442. PORTLEY MK, Scholz SW
    Hot Topic: Epigenetics in Parkinson's Disease: A New Frontier for Disease-Modifying Therapies.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28410.
    PubMed    


  443. SANTOS-GARCIA D, Pozojevic J, de Deus Fonticoba T, Kurtis M, et al
    First Case of Parkinsonian-Pyramidal Syndrome Associated with a TBK1 Mutation.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28405.
    PubMed    


  444. WALDTHALER J, Stock L, Sommerkorn J, Kruger-Zechlin C, et al
    Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease.
    Mov Disord. 2020 Nov 25. doi: 10.1002/mds.28374.
    PubMed    


  445. AL-QASSABI A, Tsao TS, Racolta A, Kremer T, et al
    Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28399.
    PubMed     Abstract available


  446. JAAKKOLA E, Huovinen A, Kaasinen V, Joutsa J, et al
    No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28400.
    PubMed    


  447. GARCIA-SANZ P, M F G Aerts J, Moratalla R
    The Role of Cholesterol in alpha-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease.
    Mov Disord. 2020 Nov 21. doi: 10.1002/mds.28396.
    PubMed     Abstract available


  448. PAGAN FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, et al
    Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
    Mov Disord. 2020 Nov 20. doi: 10.1002/mds.28389.
    PubMed     Abstract available


  449. ERREA O, Rodriguez-Oroz MC
    Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease.
    Mov Disord. 2020 Nov 18. doi: 10.1002/mds.28393.
    PubMed    


  450. OJUKWU DI, Andruska KM, Halpern CH
    Lessons From George Floyd: Racial Inequalities in the Treatment of Parkinson's Disease.
    Mov Disord. 2020 Nov 17. doi: 10.1002/mds.28388.
    PubMed    


  451. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28378.
    PubMed    


  452. OUTEIRO TF, Heutink P, Bezard E, Cenci AM, et al
    From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28387.
    PubMed     Abstract available


  453. VIGNATELLI L, Zenesini C, Belotti LMB, Baldin E, et al
    Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28408.
    PubMed     Abstract available


  454. MAETZLER W, Rochester L, Bhidayasiri R, Espay AJ, et al
    Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures.
    Mov Disord. 2020 Nov 15. doi: 10.1002/mds.28377.
    PubMed     Abstract available


  455. DEVOS D, Hirsch E, Wyse R
    Seven Solutions for Neuroprotection in Parkinson's Disease.
    Mov Disord. 2020 Nov 13. doi: 10.1002/mds.28379.
    PubMed     Abstract available


  456. DE MICCO R, Satolli S, Siciliano M, Di Nardo F, et al
    Connectivity Correlates of Anxiety Symptoms in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 10. doi: 10.1002/mds.28372.
    PubMed     Abstract available


  457. PICILLO M, Phokaewvarangkul O, Poon YY, McIntyre CC, et al
    Levodopa Versus Dopamine Agonist After Subthalamic Stimulation in Parkinson's Disease.
    Mov Disord. 2020 Nov 9. doi: 10.1002/mds.28382.
    PubMed     Abstract available


  458. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28364.
    PubMed     Abstract available


  459. SARIHAN EI, Perez-Palma E, Niestroj LM, Loesch D, et al
    Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28353.
    PubMed     Abstract available


  460. VAN DER ZEE S, Muller MLTM, Kanel P, van Laar T, et al
    Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28360.
    PubMed     Abstract available


  461. CHOUGAR L, Faouzi J, Pyatigorskaya N, Yahia-Cherif L, et al
    Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28348.
    PubMed     Abstract available


  462. DORSEY ER, Bloem BR, Okun MS
    A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.
    Mov Disord. 2020;35:1897-1902.
    PubMed     Abstract available


  463. HERRINGTON TM, Schweitzer J, Henchcliffe C, Carter BS, et al
    Toward a Personalized Approach to Parkinson's Cell Therapy.
    Mov Disord. 2020;35:2119-2120.
    PubMed    


  464. SILVA-BATISTA C, M Corcos D, B Horak F, Ugrinowitsch C, et al
    Reply to: 'Letter to the Editor on "A Randomized Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait"'.
    Mov Disord. 2020;35:2123-2124.
    PubMed    


  465. KORDOWER JH, Okun MS, Jankovic J
    Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy".
    Mov Disord. 2020;35:2120-2121.
    PubMed    


  466. NONNEKES J, Gilat M, D'Cruz N, Dijkstra BW, et al
    Letter to the Editor on "A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait".
    Mov Disord. 2020;35:2122-2123.
    PubMed    


    October 2020
  467. TAN MMX, Lawton MA, Jabbari E, Reynolds RH, et al
    Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2020 Oct 28. doi: 10.1002/mds.28342.
    PubMed     Abstract available


  468. SUN YM, Yu HL, Zhou XY, Xiong WX, et al
    Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28349.
    PubMed     Abstract available


  469. MENOZZI E, Macnaughtan J, Schapira AHV
    LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28347.
    PubMed    


  470. VAN DEN HEUVEL L, Evers L, Meinders M, Post B, et al
    Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28339.
    PubMed     Abstract available


  471. BEYLERGIL SB, Petersen M, Gupta P, Elkasaby M, et al
    Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading.
    Mov Disord. 2020 Oct 26. doi: 10.1002/mds.28352.
    PubMed     Abstract available


  472. YE Z, Zhang G, Zhang Y, Li S, et al
    The Role of the Subthalamic Nucleus in Sequential Working Memory in De Novo Parkinson's Disease.
    Mov Disord. 2020 Oct 24. doi: 10.1002/mds.28344.
    PubMed     Abstract available


  473. VAN DER HEIDE A, Meinders MJ, Speckens AEM, Peerbolte TF, et al
    Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms.
    Mov Disord. 2020 Oct 23. doi: 10.1002/mds.28345.
    PubMed     Abstract available


  474. FU JF, Matarazzo M, McKenzie J, Neilson N, et al
    Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
    Mov Disord. 2020 Oct 22. doi: 10.1002/mds.28340.
    PubMed     Abstract available


  475. YIN W, Lof M, Pedersen NL, Sandin S, et al
    Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study.
    Mov Disord. 2020 Oct 20. doi: 10.1002/mds.28314.
    PubMed     Abstract available


  476. TAKEDA A, Takahashi R, Tsuboi Y, Nomoto M, et al
    Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations.
    Mov Disord. 2020 Oct 19. doi: 10.1002/mds.28322.
    PubMed     Abstract available


  477. LOWES H, Robertson F, Pyle A, Hussain R, et al
    The human coronavirus receptor ANPEP (CD13) is overexpressed in Parkinson's disease.
    Mov Disord. 2020 Oct 18. doi: 10.1002/mds.28354.
    PubMed    


  478. SCHLOSSMACHER MG, Graybiel AM
    Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28316.
    PubMed     Abstract available


  479. TAKAMIYA A, Seki M, Kudo S, Yoshizaki T, et al
    Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28335.
    PubMed     Abstract available


  480. MESTRE TA, Kessler D, Cote D, Liddy C, et al
    Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28332.
    PubMed     Abstract available


  481. BELVISI D, Fabbrini A, De Bartolo MI, Costanzo M, et al
    The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes.
    Mov Disord. 2020 Oct 10. doi: 10.1002/mds.28321.
    PubMed     Abstract available


  482. DAHODWALA N, Li P, Jahnke J, Ladage VP, et al
    Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
    Mov Disord. 2020 Oct 8. doi: 10.1002/mds.28265.
    PubMed     Abstract available


  483. SANTIN MDN, Voulleminot P, Vrillon A, Hainque E, et al
    Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2020 Oct 6. doi: 10.1002/mds.28320.
    PubMed     Abstract available


  484. ISRAEL Z, Asch N
    Reversing a Model of Parkinson's Disease With In Situ Converted Nigral Neurons.
    Mov Disord. 2020 Oct 5. doi: 10.1002/mds.28306.
    PubMed    


  485. BONVEGNA S, Straccia G, Golfre Andreasi N, Elia AE, et al
    Parkinsonism and Nigrostriatal Damage Secondary to CSF1R-Related Primary Microgliopathy.
    Mov Disord. 2020 Oct 3. doi: 10.1002/mds.28290.
    PubMed    


  486. KANE PB, Benjamin DM, Barker RA, Lang AE, et al
    Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28319.
    PubMed     Abstract available


  487. TSUBOI T, Charbel M, Peterside DT, Rana M, et al
    Pallidal Connectivity Profiling of Stimulation-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28324.
    PubMed     Abstract available


  488. IWAKI H, Blauwendraat C, Leonard HL, Makarious MB, et al
    Differences in the Presentation and Progression of Parkinson's Disease by Sex.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28312.
    PubMed     Abstract available


  489. MUFTI K, Rudakou U, Yu E, Krohn L, et al
    Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28318.
    PubMed     Abstract available


  490. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Reply to: "Can the 2019 Novel Coronavirus Cause Parkinson's Disease?"
    Mov Disord. 2020;35:1726.
    PubMed    


  491. HURWITZ B, Lees AJ, Walusinski O
    Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease.
    Mov Disord. 2020;35:1880-1881.
    PubMed    


  492. SULLIVAN R, Yau WY, Chelban V, Rossi S, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1890-1891.
    PubMed    


  493. DA SILVA SCHMITT G, Martinez ARM, da Graca FF, de Lima FD, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1889-1890.
    PubMed    


  494. AGUIRRE-PADILLA DH, Lozano AM, Fasano A
    Reply to: "Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?"
    Mov Disord. 2020;35:1883.
    PubMed    


  495. MONTGOMERY EB JR
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020;35:1891.
    PubMed    


  496. CURY RG, Carra RB, Capato TTC, Teixeira MJ, et al
    Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?
    Mov Disord. 2020;35:1882-1883.
    PubMed    


  497. MONJE MHG, Martinez-Fernandez R
    Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?
    Mov Disord. 2020;35:1725.
    PubMed    


  498. ALVES M, Caldeira D, Reimao S, Ferro JM, et al
    N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease.
    Mov Disord. 2020;35:1886-1887.
    PubMed    


  499. CHOE CU, Petersen E, Potter-Nerger M, Buhmann C, et al
    Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease".
    Mov Disord. 2020;35:1888.
    PubMed    


  500. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease".
    Mov Disord. 2020;35:1882.
    PubMed    


  501. CROTTY GF, Lo RY, Schwarzschild MA
    If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?
    Mov Disord. 2020;35:1727-1730.
    PubMed    


    September 2020
  502. BLUMENREICH S, Jenkins BJ, Barav OB, Milenkovic I, et al
    The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28232.
    PubMed    


  503. RAJPUT AH, Kish SJ
    Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28317.
    PubMed    


  504. AL ALI J, Vaine CA, Shah S, Campion L, et al
    TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 25. doi: 10.1002/mds.28305.
    PubMed     Abstract available


  505. ZHANG X
    Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease".
    Mov Disord. 2020;35:1695.
    PubMed    


  506. LU C, Amundsen Huffmaster SL, Louie KH, Sovell-Brown K, et al
    Pallidal Oscillation Dynamics Following Cessation of Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2020;35:1697-1698.
    PubMed    


  507. SPEECKAERT MM, Speeckaert R, Delanghe JR
    Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1497.
    PubMed    


  508. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Reply to: 'Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease"'.
    Mov Disord. 2020;35:1695-1697.
    PubMed    


  509. NEUMANN WJ, Feldmann L, Kuhn AA
    Reply to: Pallidal Low-Frequency Activity in Dystonia and Subthalamic Beta Activity in Parkinson's Disease.
    Mov Disord. 2020;35:1699.
    PubMed    


  510. CEREDA E, Fasano A, Pezzoli G
    Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1498.
    PubMed    


  511. WEIL RS
    Visual Dysfunction and Parkinson's Disease.
    Mov Disord. 2020;35:1499-1501.
    PubMed    


    August 2020
  512. MARKAKI I, Bergstrom S, Tsitsi P, Remnestal J, et al
    Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28192.
    PubMed     Abstract available


    July 2020
  513. LERCHE S, Wurster I, Roben B, Zimmermann M, et al
    CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Mov Disord. 2020;35:1138-1144.
    PubMed     Abstract available


    February 2020
  514. MAHATO AK, Kopra J, Renko JM, Visnapuu T, et al
    Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
    Mov Disord. 2020;35:245-255.
    PubMed     Abstract available


  515. RAPPEL P, Grosberg S, Arkadir D, Linetsky E, et al
    Theta-alpha oscillations characterize emotional subregion in the human ventral subthalamic nucleus.
    Mov Disord. 2020;35:337-343.
    PubMed     Abstract available


  516. MARTINEZ E, Pasquereau B, Saga Y, Metereau E, et al
    The anterior caudate nucleus supports impulsive choices triggered by pramipexole.
    Mov Disord. 2020;35:296-305.
    PubMed     Abstract available


  517. LEE JY, Ahn J, Oh S, Shin JY, et al
    Retina thickness as a marker of neurodegeneration in prodromal lewy body disease.
    Mov Disord. 2020;35:349-354.
    PubMed     Abstract available


    January 2020
  518. BELLOMO G, Paciotti S, Gatticchi L, Parnetti L, et al
    The vicious cycle between alpha-synuclein aggregation and autophagic-lysosomal dysfunction.
    Mov Disord. 2020;35:34-44.
    PubMed     Abstract available


  519. PYATIGORSKAYA N, Yahia-Cherif L, Gaurav R, Ewenczyk C, et al
    Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Mov Disord. 2020;35:161-170.
    PubMed     Abstract available


  520. COUGHLIN DG, Hurtig HI, Irwin DJ
    Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
    Mov Disord. 2020;35:5-19.
    PubMed     Abstract available


  521. CHAUDHURI KR, Schrag A, Weintraub D, Rizos A, et al
    The movement disorder society nonmotor rating scale: Initial validation study.
    Mov Disord. 2020;35:116-133.
    PubMed     Abstract available


  522. RESPONDEK G, Grimm MJ, Piot I, Arzberger T, et al
    Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
    Mov Disord. 2020;35:171-176.
    PubMed     Abstract available


  523. ALCALAY RN, Hsieh F, Tengstrand E, Padmanabhan S, et al
    Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Mov Disord. 2020;35:134-141.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: